ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
고지혈증 시장 규모는 향후 수년간 안정된 성장이 전망됩니다. 2029년에는 CAGR 3.8%로 242억 4,000만 달러로 성장합니다. 예측 기간의 성장은 고지혈증 치료제 수요 증가, 세계 보건 구상, 고령화, 예방의학, 조기 개입에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 새로운 치료법, 고지혈증 관리의 디지털 헬스 기술, 고지혈증 진단 및 치료의 바이오마커, 의약품 치료의 연구개발 활동 등이 있습니다.
향후 5년간 3.8%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 인상은 벨기에와 이스라엘에서 수입되는 새로운 RNA 기반 지질 저하 요법 및 지단백 아페레시스 장비의 비용을 상승시키고, 예방적 순환기 프로그램의 비용을 악화시켜 미국 의료계에 부담을 줄 가능성이 높습니다. 또한 상호 관세와 무역 마찰 및 무역 제한의 강화로 인한 세계 경제와 무역에 대한 악영향으로 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
만성질환, 특히 심장질환의 유병률 증가는 향후 고지혈증 시장의 성장을 촉진할 것으로 예측됩니다. 심장병에는 심장과 그 기능에 영향을 미치는 다양한 질환이 포함됩니다. 고지혈증 치료는 심장마비 위험을 줄이고, 뇌졸중을 예방하고, 내피 기능을 개선하고, 침습적 시술의 필요성을 감소시켜 심장병 환자를 돕습니다. 예를 들어 2024년 9월 영국에 기반을 둔 심혈관 연구 자선단체인 British Heart Foundation이 발표한 자료에 따르면 영국에서 약 760만 명이 심장 및 순환기 질환을 앓고 있으며, 그 중 남성 약 400만 명, 여성 약 360만 명은 이러한 질환을 앓고 있는 것으로 나타났습니다. 포함되어 있는 것으로 나타났습니다. 이들 질환은 영국 전체 사망자의 약 27%를 차지하며, 매년 17만 명 이상, 하루에 약 480명이 사망하고 있으며, 이는 3분마다 1명씩 사망하는 셈입니다. 그 결과, 심장병과 같은 만성질환의 유병률 증가가 고지혈증 시장 확대를 주도하고 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 고지혈증 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 고지혈증 시장 : 성장률 분석
세계의 고지혈증 시장 실적 : 규모와 성장, 2019-2024년
세계의 고지혈증 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 고지혈증 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 고지혈증 시장 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
가족성
후천성
세계의 고지혈증 시장 : 치료별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
스타틴
PCSK9 저해제
담즙산 흡착제
콜레스테롤 흡수 저해제
피브린산 유도체
복합
기타 치료
세계의 고지혈증 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구
비경구
세계의 고지혈증 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원
전문 클리닉
홈케어
기타 최종사용자
세계의 고지혈증 시장 : 서브 세분화 가족성 고지혈증(유형별), 실적과 예측, 2019-2024년, 2024-2029년, 2034년
가족성 고콜레스테롤혈증(FH)
가족성 복합고지혈증
가족성 이상베타지단백혈증
세계의 고지혈증 시장 : 서브 세분화 후천성 고지혈증(유형별), 실적과 예측, 2019-2024년, 2024-2029년, 2034년
다이어트 관련 고지혈증
2차 고지혈증
약물 유발성 고지혈증
제7장 지역별·국가별 분석
세계의 고지혈증 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 고지혈증 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
고지혈증 시장 : 경쟁 구도
고지혈증 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Novartis AG
Sanofi-Aventis LLC.
Bristol-Myers Squibb Company
GlaxoSmithKline plc.
Eli Lilly and Co Ltd.
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd.
Daiichi Sankyo Company Limited
Sun Pharmaceutical Industries Limited
Otsuka Pharmaceutical Co. Ltd.
Menarini Group
Ipsen S.A.
Dr. Reddy's Laboratories Ltd.
Apotex Inc.
Hikma Pharmaceuticals PLC
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
고지혈증 시장 2029년 : 새로운 기회를 제공하는 국가
고지혈증 시장 2029년 : 새로운 기회를 제공하는 부문
고지혈증 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Hyperlipidemia is a medical condition marked by elevated levels of lipids (fats) in the bloodstream, including cholesterol and triglycerides. This metabolic disorder is common and represents a substantial risk factor for cardiovascular diseases.
Hyperlipidemia can be classified into two main types such as familial and acquired. Familial hyperlipidemia is a genetic disorder characterized by hereditary high lipid levels, notably cholesterol and triglycerides, significantly increasing the risk of cardiovascular diseases. Treatment options encompass medications like statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination therapies, and others. These medications can be administered orally or through injection. They serve various end-users, including hospitals, specialty clinics, home care services, and more.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The hyperlipidemia market research report is one of a series of new reports from The Business Research Company that provides hyperlipidemia market statistics, including hyperlipidemia industry global market size, regional shares, competitors with a hyperlipidemia market share, detailed hyperlipidemia market segments, market trends and opportunities and any further data you may need to thrive in the hyperlipidemia industry. This hyperlipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hyperlipidemia market size has grown steadily in recent years. It will grow from $20.24 billion in 2024 to $20.92 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to growing demand for effective treatments, geographic expansion, growing public awareness of hyperlipidemia, tobacco use.
The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $24.24 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to growing demand for hyperlipidemia drugs, global health initiatives, aging population, preventive care and early intervention. Major trends in the forecast period include novel therapies, digital health technologies in hyperlipidemia management, biomarkers in hyperlipidemia diagnosis and treatment, research & development activities of pharmaceuticals treatments.
The forecast of 3.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. healthcare by driving up the cost of novel RNA-based lipid-lowering therapies and lipoprotein apheresis machines imported from Belgium and Israel, exacerbating preventive cardiology program expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising incidence of chronic disorders, particularly heart disease, is expected to drive the growth of the hyperlipidemia market in the future. Heart diseases encompass various conditions that impact the heart and its functioning. Treatment for hyperlipidemia assists individuals with heart disease by reducing the risk of heart attacks, preventing strokes, improving endothelial function, and decreasing the necessity for invasive procedures. For instance, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, revealed that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including about 4 million males and 3.6 million females living with these conditions. These diseases account for around 27% of all deaths in the UK, resulting in over 170,000 deaths each year, or roughly 480 deaths per day, which translates to one death every three minutes. Consequently, the increasing prevalence of chronic disorders such as heart disease is driving the expansion of the hyperlipidemia market.
The increasing prevalence of smoking is expected to drive the growth of the hyperlipidemia market in the future. Smoking involves the consumption of tobacco through combustion, leading to the inhalation of smoke and the absorption of various components into the bloodstream. Smoking is closely linked to risk factors associated with hyperlipidemia, such as obesity and insulin resistance. These risk factors can contribute to dyslipidemia, characterized by abnormal lipid levels, which can eventually lead to the development of hyperlipidemia. For example, in July 2022, Statistics Canada, a Canadian government agency, reported a 5.8% increase in cigarette production compared to June 2021, with total cigarette sales reaching 1.4 billion in June 2022. Therefore, the growing prevalence of smoking is a driving factor in the hyperlipidemia market.
Key players in the hyperlipidemia market are concentrating on developing innovative products, including advanced therapies for lowering low-density lipoprotein cholesterol, to maintain their market position. For instance, in March 2024, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, announced the approval of Praluent (alirocumab) Injection by the U.S. Food & Drug Administration (FDA). This represents a significant advancement in the treatment of heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 8 and older, providing a targeted method to manage dangerously high low-density lipoprotein cholesterol (LDL-C) levels. The recent FDA approval is backed by Phase 3 trial results, which demonstrated a 31% reduction in LDL-C levels with regular dosing. Its well-established safety profile, consistent with that observed in adults, offers reassurance to families and healthcare providers. Additionally, as the first therapy targeting the genetically-validated PCSK9 protein, Praluent marks a milestone in heart disease treatment. Together, these attributes position Praluent as an essential option for managing high cholesterol in children with HeFH.
In March 2022, Pfizer Inc., a U.S.-based pharmaceutical and biotechnology firm, finalized the acquisition of Arena Pharmaceuticals for an undisclosed sum. This strategic move by Pfizer is driven by the company's goal of broadening its product portfolio through the addition of Arena Pharmaceuticals' ongoing clinical-stage projects, which hold promise for the advancement of innovative therapies targeting various immuno-inflammatory diseases. Arena Pharmaceuticals, situated in the United States, is recognized for its specialization in biopharmaceuticals and the development of medications, including those designed to address high cholesterol and hyperlipidemia.
Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.
North America was the largest region in the hyperlipidemia market in 2024. The regions covered in hyperlipidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hyperlipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hyperlipidemia market consists of revenues earned by entities by providing weight management, surgeries and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperlipidemia market also includes sales of niacin (nicotinic acid), omega-3 fatty acid supplements, ezetimibe, resins, adenosine triphosphate-citrate lyase (ACL) inhibitors, lomitapide and mipomersen. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hyperlipidemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hyperlipidemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for hyperlipidemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hyperlipidemia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Familial; Acquired
2) By Treatment: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Combination; Other Treatment
3) By Route of Administration: Oral; Parenteral
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Hyperlipidemia Market Characteristics
3. Hyperlipidemia Market Trends And Strategies
4. Hyperlipidemia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Hyperlipidemia Growth Analysis And Strategic Analysis Framework
5.1. Global Hyperlipidemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hyperlipidemia Market Growth Rate Analysis
5.4. Global Hyperlipidemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hyperlipidemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hyperlipidemia Total Addressable Market (TAM)
6. Hyperlipidemia Market Segmentation
6.1. Global Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Familial
Acquired
6.2. Global Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Statins
PCSK9 Inhibitors
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibric Acid Derivatives
Combination
Other Treatment
6.3. Global Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.4. Global Hyperlipidemia Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End Users
6.5. Global Hyperlipidemia Market, Sub-Segmentation Of Familial Hyperlipidemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Familial Hypercholesterolemia (FH)
Familial Combined Hyperlipidemia
Familial Dysbetalipoproteinemia
6.6. Global Hyperlipidemia Market, Sub-Segmentation Of Acquired Hyperlipidemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diet-Related Hyperlipidemia
Secondary Hyperlipidemia
Drug-Induced Hyperlipidemia
7. Hyperlipidemia Market Regional And Country Analysis
7.1. Global Hyperlipidemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hyperlipidemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Hyperlipidemia Market
8.1. Asia-Pacific Hyperlipidemia Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Hyperlipidemia Market
9.1. China Hyperlipidemia Market Overview
9.2. China Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Hyperlipidemia Market
10.1. India Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Hyperlipidemia Market
11.1. Japan Hyperlipidemia Market Overview
11.2. Japan Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Hyperlipidemia Market
12.1. Australia Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Hyperlipidemia Market
13.1. Indonesia Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Hyperlipidemia Market
14.1. South Korea Hyperlipidemia Market Overview
14.2. South Korea Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Hyperlipidemia Market
15.1. Western Europe Hyperlipidemia Market Overview
15.2. Western Europe Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Hyperlipidemia Market
16.1. UK Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Hyperlipidemia Market
17.1. Germany Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Hyperlipidemia Market
18.1. France Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Hyperlipidemia Market
19.1. Italy Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Hyperlipidemia Market
20.1. Spain Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Hyperlipidemia Market
21.1. Eastern Europe Hyperlipidemia Market Overview
21.2. Eastern Europe Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Hyperlipidemia Market
22.1. Russia Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Hyperlipidemia Market
23.1. North America Hyperlipidemia Market Overview
23.2. North America Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Hyperlipidemia Market
24.1. USA Hyperlipidemia Market Overview
24.2. USA Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Hyperlipidemia Market
25.1. Canada Hyperlipidemia Market Overview
25.2. Canada Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Hyperlipidemia Market
26.1. South America Hyperlipidemia Market Overview
26.2. South America Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Hyperlipidemia Market
27.1. Brazil Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Hyperlipidemia Market
28.1. Middle East Hyperlipidemia Market Overview
28.2. Middle East Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Hyperlipidemia Market
29.1. Africa Hyperlipidemia Market Overview
29.2. Africa Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Hyperlipidemia Market Competitive Landscape And Company Profiles
30.1. Hyperlipidemia Market Competitive Landscape
30.2. Hyperlipidemia Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Hyperlipidemia Market Other Major And Innovative Companies
31.1. Novartis AG
31.2. Sanofi-Aventis LLC.
31.3. Bristol-Myers Squibb Company
31.4. GlaxoSmithKline plc.
31.5. Eli Lilly and Co Ltd.
31.6. Boehringer Ingelheim International GmbH
31.7. Teva Pharmaceutical Industries Ltd.
31.8. Daiichi Sankyo Company Limited
31.9. Sun Pharmaceutical Industries Limited
31.10. Otsuka Pharmaceutical Co. Ltd.
31.11. Menarini Group
31.12. Ipsen S.A.
31.13. Dr. Reddy's Laboratories Ltd.
31.14. Apotex Inc.
31.15. Hikma Pharmaceuticals PLC
32. Global Hyperlipidemia Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Hyperlipidemia Market
34. Recent Developments In The Hyperlipidemia Market
35. Hyperlipidemia Market High Potential Countries, Segments and Strategies
35.1 Hyperlipidemia Market In 2029 - Countries Offering Most New Opportunities
35.2 Hyperlipidemia Market In 2029 - Segments Offering Most New Opportunities
35.3 Hyperlipidemia Market In 2029 - Growth Strategies
